IP Library Granted Patent US 6,939,852
Granted Patent B2
US 6,939,852 · App. 10/104,899 · Granted Sep 6, 2005

Methods and compositions for the treatment of cerebral palsy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,939,852
App. No.
10/104,899
Granted
Sep 6, 2005
Kind
B2
Abstract

The invention provides for the use of a botulinum toxin to treat cerebral palsy in juvenile patients by transdermal administration of the botulinum toxin. The juvenile patients are preferably juveniles of up to 6 years in age.

Claims (12)

1. A method for treating juvenile cerebral palsy, the method comprising the step of transdermal administration of a botulinum toxin type A to a juvenile cerebral palsy patient, thereby treating juvenile cerebral palsy.

2. The method of claim 1 wherein the botulinum toxin type A is transdermally administered into a spastic muscle of the patient.

3. The method of claim 1 wherein the botulinum toxin type A is transdermally administered into a calf muscle or hamstring of the patient.

4. The method of claim 1 , wherein the transdermal administration step is carried out by contacting a skin surface of the patient with a botulinum toxin depot which can release the botulinum toxin type A for absorption through the skin of the patient.

5. The method of claim 4 , wherein the botulinum toxin depot is an adhesive patch which comprises a polymeric carrier for the botulinum toxin type A.

6. A method of treating juvenile cerebral palsy, the method comprising the step of transdermal administration of a therapeutically effective amount of a botulinum toxin type A to a juvenile cerebral palsy patient by contacting a skin surface of the patient with a botulinum toxin type A depot comprising a polymeric carrier which carrier can release the botulinum toxin type A for absorption through the skin surface of the patient, thereby treating juvenile cerebral palsy.

7. The method of claim 6 , further comprising the step of pretreatment of the skin with a skin permeation enhancer prior to contacting the skin surface of the patient with the botulinum toxin type A depot.

8. The method of claim 7 , further comprising the step of iontophoresis of the skin after the pretreatment step to thereby further enhance transdermal delivery of the botulinum toxin.

9. A method of treating a juvenile cerebral palsy, the method comprising the steps of:

(a) pretreatment of a skin surface of a juvenile cerebral palsy patient with a skin permeation enhancer;

(b) transdermal administration of a therapeutically effective amount of a botulinum toxin type A to a juvenile cerebral palsy patient by contacting the skin surface of the patient with a botulinum toxin type A depot comprising a polymeric carrier which carrier can release the botulinum toxin type A for absorption through the skin surface of the patient, and;

(c) iontophoresis of the skin to further enhance transdermal delivery of the botulinum toxin, thereby treating juvenile cerebral palsy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2003
From: ALLERGAN SALES, INC. (MERGED INTO ALLERGAN SALES, LLC 6/3/2002)
To: ALLERGAN, INC.
Reel/Frame 013898/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2002
From: GRAHAM, HERBERT KERR
To: ALLERGAN SALES, INC.
Reel/Frame 012778/0023 →